Details of the Drug Combination

General Information of Drug Combination (ID: DCPNBON)

Drug Combination Name
Heparin Minocycline
Indication
Disease Entry Status REF
Acute Ischemic Stroke Phase 1 [1]
Component Drugs Heparin   DM4ZP3W Minocycline   DMVN5OH
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Heparin
Disease Entry ICD 11 Status REF
Aplastic anemia 3A70 Approved [2]
Bacteremia 1A73 Approved [2]
Burns N.A. Approved [2]
Coronary heart disease BA80.Z Approved [2]
Deep vein thrombosis BD71 Approved [2]
Disseminated intravascular coagulation 3B20 Approved [2]
Metabolic disorder 5C50-5D2Z Approved [2]
Pneumonia CA40 Approved [2]
Pulmonary embolism BB00 Approved [2]
Venous thrombosis BA43 Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [4]
Diabetic angiopathy BD53.Y Investigative [2]
Indication(s) of Minocycline
Disease Entry ICD 11 Status REF
Acne vulgaris ED80 Approved [5]
Actinomycosis N.A. Approved [5]
Acute gonococcal cervicitis N.A. Approved [5]
Bacterial infection 1A00-1C4Z Approved [6]
Bartonellosis N.A. Approved [5]
Bronchitis CA20 Approved [5]
Brucellosis N.A. Approved [5]
Chancroid N.A. Approved [5]
Listeriosis N.A. Approved [5]
Lymphogranuloma venereum N.A. Approved [5]
Ornithosis N.A. Approved [5]
Periodontitis DA0C Approved [5]
Pneumonia CA40 Approved [5]
Q fever N.A. Approved [5]
Relapsing fever N.A. Approved [5]
Rickettsialpox N.A. Approved [5]
Rocky mountain spotted fever N.A. Approved [5]
Syphilis N.A. Approved [5]
Trachoma N.A. Approved [5]
Tularemia 1B94 Approved [5]
Typhus N.A. Approved [5]
Urinary tract infection GC08 Approved [5]
Yaws N.A. Approved [5]
Rosacea ED90.0 Phase 2 [7]
Plague N.A. Investigative [5]
Sinusitis CA0A.Z Investigative [5]
Vibrio cholerae infection 1A00 Investigative [5]
Minocycline Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) TTQ8KVI F4NA87_STAAU Binder [8]
------------------------------------------------------------------------------------
Minocycline Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 2E1 (CYP2E1) OTHQ17JG CP2E1_HUMAN Increases ADR [9]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00836355) Enoxaparin and/or Minocycline in Acute Stroke
2 Heparin FDA Label
3 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 090809.
4 Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020 Dec;9(1):727-732.
5 Minocycline FDA Label
6 Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother. 2006 Jun;50(6):2156-66.
9 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.